drugset

drugset / Trial / NCT02557958

Chronic Obstructive Pulmonary Disease Transcription Factor and Cytokine Study

NCT02557958 ↗

Phase 0 Completed 19 enrolled NYU Langone Health

RandomizedParallel-groupDouble-blindTreatment

Summary

Chronic Obstructive Pulmonary Disease Transcription Factor and Cytokine Study.

Timeline

Start: 2009-01
Primary completion: 2018-12
Completion: 2018-12

Publications

Segal LN, Clemente JC, Wu BG, Wikoff WR, Gao Z, Li Y, Ko JP, Rom WN, Blaser MJ, Weiden MD. Randomised, double-blind, placebo-controlled trial with azithromycin selects for anti-inflammatory microbial metabolites in the emphysematous lung. Thorax. 2017 Jan;72(1):13-22. doi: 10.1136/thoraxjnl-2016-208599. Epub 2016 Aug 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Azithromycin	Small molecule	250 mg	—

Indications